40:I[185,["/_next/static/chunks/3xnt26d00_zk-.js","/_next/static/chunks/1s-yni1uf2lwd.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/06x30xgfe6iur.js","/_next/static/chunks/3b4qrzgkt_l12.js","/_next/static/chunks/15lgs8s22dk5l.js"],"SendEmailButton"] 42:I[63625,["/_next/static/chunks/3xnt26d00_zk-.js","/_next/static/chunks/1s-yni1uf2lwd.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/06x30xgfe6iur.js","/_next/static/chunks/3b4qrzgkt_l12.js","/_next/static/chunks/15lgs8s22dk5l.js"],"AddToLibraryButton"] 43:I[29721,["/_next/static/chunks/3xnt26d00_zk-.js","/_next/static/chunks/1s-yni1uf2lwd.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/06x30xgfe6iur.js","/_next/static/chunks/3b4qrzgkt_l12.js","/_next/static/chunks/15lgs8s22dk5l.js"],"ShareButton"] 44:I[58016,["/_next/static/chunks/3xnt26d00_zk-.js","/_next/static/chunks/1s-yni1uf2lwd.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/06x30xgfe6iur.js","/_next/static/chunks/3b4qrzgkt_l12.js","/_next/static/chunks/15lgs8s22dk5l.js"],"ProcessEpisodeButton"] 45:I[45269,["/_next/static/chunks/3xnt26d00_zk-.js","/_next/static/chunks/1s-yni1uf2lwd.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/06x30xgfe6iur.js","/_next/static/chunks/3b4qrzgkt_l12.js","/_next/static/chunks/15lgs8s22dk5l.js"],"SignupCTA"] 3a:["$","div",null,{"className":"flex flex-wrap items-center gap-x-4 gap-y-1 font-mono text-[12px] uppercase tracking-[0.1em] text-[color:var(--fg-3)]","children":[["$","time",null,{"dateTime":"2026-07-21T11:45:02.000Z","children":"July 21, 2026"}],["$","span",null,{"aria-hidden":true,"children":"·"}],["$","span",null,{"children":"00:05:06"}],false]}] 41:T476,

Dr. Marco Donadini highlights the next generation of antithrombotic therapies at the ISTH 2026 Congress, featuring these breakthrough presentations:

- A Synthetic, Allosteric, Highly Selective, Reversible Inhibitor of Human Factor XIa for Venous and Lung (Cancer-Associated) Thrombosis – Umesh Desai (Richmond, US)

- EXocite ACTive site (EXACT) Inhibitors as Potent RNA Aptamer-Based Anticoagulants Targeting Various Coagulation Factors – Jeffrey Clancy (Durham, US)

- Efficacy-Safety Paradox of Next-Gen Factor XI/XIa Inhibitors: Meta-Analysis of Phase 2 and 3 Trials – Rahul Falodia (Jodhpur, India)

- BAY 3389934: A Dual Factor IIa/Xa Inhibitor – Nicole Juffermans (Rotterdam, The Netherlands)

- REGN9533, a monoclonal antibody targeting Factor XII (FXII), Phase 1 study – Frédéric Vanhoutte (Antwerp, Belgium)

Video: https://medicaldigest.org/scientific-contents/interview:future-anticoagulants